Medicare patients get faster care—if insurers don't raise premiums to compensate

What it does

This bill prohibits Medicare Advantage plans from requiring prior authorization (advance approval from insurers before patients receive care) for most medical services starting January 2027, and blocks the federal government from testing prior authorization models in traditional Medicare. It also requires physician review of any AI-driven coverage denials and mandates public notice-and-comment before testing new payment models.

Why we flagged it

The bill's core mechanism is removing a procedural barrier (prior authorization) that insurers use to delay or deny care, and restricting AI-driven denials without physician oversight. This is consumer protection regulation, not a tax or spending measure.

What the text implies

• Eliminates a key cost-control tool for Medicare Advantage plans; insurers may offset by raising premiums, narrowing provider networks, or increasing cost-sharing on other services not covered by the ban.
• The physician-review requirement for AI denials may create bottlenecks if not resourced adequately, potentially delaying coverage decisions rather than accelerating them.
• Traditional Medicare remains subject to prior authorization under existing law (Parts A and B); the bill only blocks NEW testing models, leaving current beneficiaries unprotected.
• The bill does not address prior authorization for Part D drugs (prescription coverage), which remains a major source of patient delays and denials in Medicare Advantage.
• Public notice-and-comment requirement for future CMI models may slow innovation testing but increases transparency and stakeholder input on payment experiments.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Patients gain faster access to care by eliminating insurer gatekeeping through prior authorization, which studies show delays necessary treatment and increases denials. The bill protects patients from opaque AI-driven coverage decisions by requiring physician review. However, insurers may respond by raising premiums or narrowing networks, creating a mixed but net-positive outcome for most beneficiaries.

Who stands to gain

• healthcare providers (reduced administrative burden from prior authorization requests)
• pharmaceutical companies (faster patient access to drugs, though Part D carve-out limits impact)

Named in the bill

Medicare Advantage plans, Centers for Medicare & Medicaid Services (CMS), Center for Medicare and Medicaid Innovation (CMMI), WISeR Model (Wasteful and Inappropriate Services Reduction), Medicare Administrative Contractors, HHS Secretary

Where it stands

6 cosponsors: 6 Democrats.

• Apr 20, 2026 — Introduced · Congress.gov: “Introduced in House”
• Apr 20, 2026 — Referred to House Committee on Energy and Commerce and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.